KR20170138573A - 당뇨병 치료 조성물 및 치료방법 - Google Patents

당뇨병 치료 조성물 및 치료방법 Download PDF

Info

Publication number
KR20170138573A
KR20170138573A KR1020177034790A KR20177034790A KR20170138573A KR 20170138573 A KR20170138573 A KR 20170138573A KR 1020177034790 A KR1020177034790 A KR 1020177034790A KR 20177034790 A KR20177034790 A KR 20177034790A KR 20170138573 A KR20170138573 A KR 20170138573A
Authority
KR
South Korea
Prior art keywords
composition
matrix
colon
diabetes
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177034790A
Other languages
English (en)
Korean (ko)
Inventor
젤지 리스자드 셰브치크
Original Assignee
바이오키어 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오키어 인코포레이티드 filed Critical 바이오키어 인코포레이티드
Publication of KR20170138573A publication Critical patent/KR20170138573A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020177034790A 2009-01-12 2010-01-11 당뇨병 치료 조성물 및 치료방법 Ceased KR20170138573A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14395109P 2009-01-12 2009-01-12
US61/143,951 2009-01-12
US29377310P 2010-01-11 2010-01-11
US61/293,773 2010-01-11
PCT/US2010/020629 WO2010081079A2 (en) 2009-01-12 2010-01-11 Composition and method for treatment of diabetes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177007518A Division KR20170034928A (ko) 2009-01-12 2010-01-11 당뇨병 치료 조성물 및 치료방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197015093A Division KR20190062609A (ko) 2009-01-12 2010-01-11 당뇨병 치료 조성물 및 치료방법

Publications (1)

Publication Number Publication Date
KR20170138573A true KR20170138573A (ko) 2017-12-15

Family

ID=42317190

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020177034790A Ceased KR20170138573A (ko) 2009-01-12 2010-01-11 당뇨병 치료 조성물 및 치료방법
KR1020117015982A Ceased KR20110120866A (ko) 2009-01-12 2010-01-11 당뇨병 치료 조성물 및 치료방법
KR1020177007518A Ceased KR20170034928A (ko) 2009-01-12 2010-01-11 당뇨병 치료 조성물 및 치료방법
KR1020197015093A Ceased KR20190062609A (ko) 2009-01-12 2010-01-11 당뇨병 치료 조성물 및 치료방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020117015982A Ceased KR20110120866A (ko) 2009-01-12 2010-01-11 당뇨병 치료 조성물 및 치료방법
KR1020177007518A Ceased KR20170034928A (ko) 2009-01-12 2010-01-11 당뇨병 치료 조성물 및 치료방법
KR1020197015093A Ceased KR20190062609A (ko) 2009-01-12 2010-01-11 당뇨병 치료 조성물 및 치료방법

Country Status (23)

Country Link
US (2) US8470885B2 (https=)
EP (1) EP2376077B1 (https=)
JP (1) JP5702306B2 (https=)
KR (4) KR20170138573A (https=)
CN (1) CN102355896A (https=)
AU (1) AU2010203413B2 (https=)
BR (1) BRPI1006145B8 (https=)
CA (1) CA2748827C (https=)
CL (1) CL2011001692A1 (https=)
CY (1) CY1119010T1 (https=)
DK (1) DK2376077T3 (https=)
EA (1) EA022631B1 (https=)
ES (1) ES2628233T3 (https=)
HR (1) HRP20170886T1 (https=)
HU (1) HUE034551T2 (https=)
LT (1) LT2376077T (https=)
MX (1) MX2011007393A (https=)
PL (1) PL2376077T3 (https=)
PT (1) PT2376077T (https=)
RS (1) RS56054B1 (https=)
SI (1) SI2376077T1 (https=)
SM (1) SMT201700278T1 (https=)
WO (1) WO2010081079A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509892A (ja) * 2008-11-26 2012-04-26 サティオゲン ファーマシューティカルズ，インク． サティオゲン類を含有する組成物及び使用の方法
US20220071895A1 (en) * 2009-01-12 2022-03-10 Biokier, Inc. Composition and method for treatment of diabetes
US20150224081A1 (en) * 2009-01-12 2015-08-13 Biokier, Inc. Composition and method for treatment of diabetes
WO2012161670A2 (en) 2010-04-07 2012-11-29 Incube Labs, Llc Method for treating diabetes and other glucose regulation disorders using stem cells
CN103429739B (zh) 2010-05-12 2018-11-13 哥伦比亚大学纽约管理委员会 制备产生和分泌胰岛素的肠内分泌细胞的方法
CN103702668A (zh) * 2011-05-02 2014-04-02 拜奥基尔公司 治疗糖尿病的组合物和方法
KR20130055220A (ko) 2011-11-18 2013-05-28 삼성전자주식회사 동박적층판 및 이를 사용한 금속코어기판의 제조방법
CN108478551A (zh) * 2011-11-21 2018-09-04 埃默斯医疗股份有限公司 用于治疗糖尿病和相关病症的方法和组合物
US20150073057A1 (en) * 2013-09-06 2015-03-12 Biokier, Inc. Composition and method for treatment of diabetes
EP3160503B1 (en) 2014-06-26 2021-02-17 The Trustees of Columbia University in the City of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
WO2016172479A1 (en) * 2015-04-22 2016-10-27 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
WO2016210384A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
US9668991B1 (en) 2015-12-09 2017-06-06 International Business Machines Corporation SCFA colonic composition
CN107684550B (zh) * 2016-08-03 2020-04-10 徐天宏 糖尿病治疗产品及其制备与应用
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2019165309A1 (en) 2018-02-23 2019-08-29 Ambra Bioscience Llc Compositions and methods for hunger control and weight management
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
CN114340615A (zh) 2019-08-12 2022-04-12 麻省理工学院 用于施用治疗剂的制品和方法
US20230190686A1 (en) * 2021-12-17 2023-06-22 Biokier, Inc. Composition and method for treatment of diabetes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA885473B (en) 1987-08-07 1989-03-29 Century Lab Inc Free fatty acids for treatment of diabetes mellitus
IT1245890B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
PT1003476E (pt) 1997-08-11 2005-05-31 Alza Corp Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
US6652882B1 (en) 1997-10-06 2003-11-25 Intellipharmaceutics Corp Controlled release formulation containing bupropion
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
IL142650A (en) * 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
EP1183014B1 (en) 1999-06-14 2003-10-08 Cosmo S.p.A. Controlled release and taste masking oral pharmaceutical compositions
CA2438593C (en) 2001-02-26 2010-09-21 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
US20030203004A1 (en) 2002-04-24 2003-10-30 Kelm Gary Robert Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
ES2240931T3 (es) 2003-10-28 2005-10-16 Adorkem Technology Spa Procedimiento para la preparacion de citalopram.
ITMI20040187A1 (it) 2004-02-06 2004-05-06 Cosmo Spa Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali
ITMI20041295A1 (it) 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
JP2006056881A (ja) 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
JP2006063064A (ja) 2004-07-27 2006-03-09 Takeda Chem Ind Ltd 受容体作動剤
EP1884513A4 (en) 2005-05-23 2010-04-28 Japan Tobacco Inc PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME
DE102005046237A1 (de) 2005-09-28 2007-04-05 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen
ITMI20052000A1 (it) 2005-10-21 2007-04-22 Promefarm S R L Compressa gastroresitente a base di butirrato di sodio
CN101404987A (zh) 2006-01-20 2009-04-08 史密丝克莱恩比彻姆公司 磺酰胺衍生物在治疗代射和神经系统疾病中的用途
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
AU2007331447B2 (en) * 2006-12-15 2012-09-06 Tima Foundation Novel compositions and uses thereof
CA2744817C (en) 2008-11-26 2020-07-07 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
JP2012509892A (ja) 2008-11-26 2012-04-26 サティオゲン ファーマシューティカルズ，インク． サティオゲン類を含有する組成物及び使用の方法
SI2395991T1 (sl) 2009-02-10 2013-12-31 Amarin Pharmaceuticals Ireland Limited Uporaba etil estra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije
EP3318255B1 (en) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same

Also Published As

Publication number Publication date
MX2011007393A (es) 2011-10-06
SMT201700278T1 (it) 2017-07-18
EP2376077B1 (en) 2017-03-15
JP2012515163A (ja) 2012-07-05
AU2010203413B2 (en) 2015-05-14
US20110275716A1 (en) 2011-11-10
US8470885B2 (en) 2013-06-25
KR20110120866A (ko) 2011-11-04
RS56054B1 (sr) 2017-09-29
EA201190068A1 (ru) 2012-01-30
EP2376077A2 (en) 2011-10-19
AU2010203413A1 (en) 2011-07-14
WO2010081079A2 (en) 2010-07-15
ES2628233T3 (es) 2017-08-02
BRPI1006145A2 (pt) 2017-05-30
US20130102581A1 (en) 2013-04-25
CA2748827C (en) 2017-10-10
EA022631B1 (ru) 2016-02-29
CY1119010T1 (el) 2018-01-10
DK2376077T3 (en) 2017-06-26
SI2376077T1 (sl) 2017-09-29
HRP20170886T1 (hr) 2017-09-08
HUE034551T2 (en) 2018-02-28
KR20170034928A (ko) 2017-03-29
JP5702306B2 (ja) 2015-04-15
CA2748827A1 (en) 2010-07-15
CN102355896A (zh) 2012-02-15
KR20190062609A (ko) 2019-06-05
US8680085B2 (en) 2014-03-25
WO2010081079A3 (en) 2010-11-25
BRPI1006145B8 (pt) 2021-05-25
CL2011001692A1 (es) 2012-04-13
PL2376077T3 (pl) 2017-10-31
LT2376077T (lt) 2017-08-10
EP2376077A4 (en) 2012-08-29
PT2376077T (pt) 2017-06-23
BRPI1006145B1 (pt) 2021-03-09

Similar Documents

Publication Publication Date Title
KR20170138573A (ko) 당뇨병 치료 조성물 및 치료방법
US9301938B2 (en) Composition and method for treatment of diabetes
AU2012250877B2 (en) Composition and method for treatment of diabetes
US9006288B2 (en) Composition and method for treatment of diabetes
US20190262262A1 (en) Composition and method for treatment of diabetes
US20150224081A1 (en) Composition and method for treatment of diabetes
US20230149300A1 (en) Composition and method for treatment of diabetes
US20220071895A1 (en) Composition and method for treatment of diabetes
US20220054406A1 (en) Composition and method for treatment of diabetes
US20230133176A1 (en) Composition and method for treatment of diabetes
CN109730986A (zh) 治疗糖尿病的组合物和方法

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20171201

Application number text: 1020177007518

Filing date: 20170317

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171227

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180219

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20181226

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180219

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20181226

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180820

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190327

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190225

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20181226

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180820

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180219

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190524

Application number text: 1020177007518

Filing date: 20170317